Compare SMHI & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMHI | LCTX |
|---|---|---|
| Founded | 1989 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.5M | 255.4M |
| IPO Year | 2016 | 1996 |
| Metric | SMHI | LCTX |
|---|---|---|
| Price | $8.74 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 79.3K | ★ 1.1M |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.41 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $173,783,000.00 | $14,556,000.00 |
| Revenue This Year | $1.21 | $109.40 |
| Revenue Next Year | $9.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $5.55 | $0.91 |
| 52 Week High | $10.00 | $2.09 |
| Indicator | SMHI | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.33 | 47.73 |
| Support Level | $6.97 | $1.02 |
| Resistance Level | $10.00 | $1.18 |
| Average True Range (ATR) | 0.27 | 0.06 |
| MACD | -0.12 | -0.00 |
| Stochastic Oscillator | 8.33 | 49.98 |
Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that (i) deliver cargo and personnel to offshore installations, including offshore wind farms, (ii) assist offshore operations for production and storage facilities, (iii) provide construction, well work-over, offshore wind farm installation and decommissioning support and (iv) carry and launch equipment used underwater in drilling and well installation, maintenance, inspection and repair. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America, with the majority of revenue deriving from the Africa and Europe segment.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.